Physician profile
Michael P Mincolla
NPI 1851546014
$7,801.64
in general payments reported to CMS, 2019-2025
44 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $359 · 2021: $580 · 2022: $487 · 2023: $1,464 · 2024: $1,776 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,966.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.65 | 2020-2025 | |
| Pfizer INC. | $865.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $597.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $593.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $460.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $428.76 | 2019-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $406.03 | 2023-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $267.09 | 2021-2025 | |
| Allergan, INC. | $245.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.39 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $186.60 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $180.99 | 2019-2023 | Austedo Xr |
| Astellas Pharma US INC | $179.29 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $165.88 | 2019-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $136.42 | 2020-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $134.74 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $126.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.82 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $117.20 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Lundbeck LLC | $103.79 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $93.70 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $68.17 | 2024-2025 | Nexletol |
| Corium, LLC | $54.17 | 2023-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $44.92 | 2019 | |
| Merck Sharp & Dohme LLC | $41.34 | 2023 | Vaxelis, M-M-R II, Vaxneuvance |
| Exact Sciences Corporation | $35.96 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Mannkind Corporation | $33.83 | 2019 | |
| Vyne Pharmaceuticals INC. | $30.82 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.83 | 2022 | |
| Corcept Therapeutics | $28.55 | 2025 | Korlym |
| Ucb, INC. | $21.61 | 2024 | Nayzilam |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $20.25 | 2021 | |
| Axonics, INC. | $19.12 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.89 | 2021 | |
| Aimmune Therapeutics, INC. | $16.64 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.54 | 2023 | Quviviq |
| Biogen, INC. | $14.01 | 2025 | Zurzuvae |
| Renalytix Ai, INC. | $13.80 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Insulet Corporation | $13.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.48 | 2019 | |
| Genentech USA, INC. | $11.33 | 2020 | |
| Neuronetics, INC. | $9.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mincolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.